{"id":4220,"date":"2026-11-11T09:00:00","date_gmt":"2026-11-11T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4220"},"modified":"2026-11-11T20:45:31","modified_gmt":"2026-11-12T00:45:31","slug":"neurosterix-closes-105-million-series-b","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4220","title":{"rendered":"Neurosterix Closes $105 Million Series B"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"768\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Neurosterix_Deal_and_Financing-768x768.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4229\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Neurosterix_Deal_and_Financing-768x768.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Neurosterix_Deal_and_Financing-300x300.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Neurosterix_Deal_and_Financing-1024x1024.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Neurosterix_Deal_and_Financing-150x150.png 150w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Neurosterix_Deal_and_Financing.png 1254w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Neurosterix; Addex Therapeutics<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Series B financing ($105 million)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Small molecule (oral M4 positive allosteric modulator)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>NTX-253<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Muscarinic M4 receptor<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Schizophrenia<\/p>\n<h4>Summary<\/h4>\n<p>Addex disclosed November 11 that its 2024 spinout Neurosterix closed a $105 million Series B to advance NTX-253 toward Phase 2 schizophrenia development. This is newly closed capital, not an announced target.<\/p>\n<p>Addex did not join the round and reports an 8.5% remaining equity interest valued at $18.6 million. NTX-253 is an oral selective muscarinic M4 positive allosteric modulator; the company says Phase 1 single- and multiple-dose studies are complete.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> financing enables a rigorous efficacy test of selective M4 modulation in psychosis. Support: completed first-in-human studies and sizeable new capital. Against: no Phase 2 effect or disclosed runway in the release.<\/p>\n<p><strong>Interpretation B:<\/strong> selective M4 pharmacology may not translate into adequate efficacy or tolerability at useful exposure. Support: schizophrenia endpoints and long-term safety are demanding. Against: clinical target rationale and phase progression support testing. Prespecified symptom endpoints, exposure-response, cholinergic events, cognitive effects, trial enrollment and spend will test the thesis. Lead investors were not named in the parent release.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Neurosterix is an Addex spinout developing small-molecule allosteric modulators. NTX-253 potentiates M4 receptor signaling, intended to modulate dopamine circuits without direct D2 blockade.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>The $105 million Series B is closed capital disclosed by the parent company.<\/li>\n<li>Addex did not participate and retains an 8.5% equity interest valued at $18.6 million.<\/li>\n<li>Lead investors and runway were not named.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>Substantial funding for a selective M4 approach heading into Phase 2. Efficacy and tolerability remain untested in patients.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 3 of 5. Signal Direction: neutral. Confidence in Facts: high. Confidence in Interpretation: low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Addex disclosed November 11 that its 2024 spinout Neurosterix closed a $105 million Series B to advance NTX-253 toward Phase 2 schizophrenia development. This is newly closed capital, not an announced target.<\/p>\n","protected":false},"author":1,"featured_media":4229,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[1448,1447,1449],"class_list":["post-4220","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-addex","tag-neurosterix","tag-ntx-253"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4220"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4220\/revisions"}],"predecessor-version":[{"id":4253,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4220\/revisions\/4253"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4229"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}